Edwards Lifesciences (NYSE:EW) Upgraded to “Strong-Buy” at Wall Street Zen

Edwards Lifesciences (NYSE:EW) was upgraded by Wall Street Zen from a “buy” rating to a “strong-buy” rating in a research report issued on Sunday.

Several other analysts have also commented on EW. JPMorgan Chase & Co. boosted their price target on Edwards Lifesciences from $80.00 to $85.00 and gave the company a “neutral” rating in a research note on Friday, July 25th. Royal Bank Of Canada boosted their price target on Edwards Lifesciences from $85.00 to $89.00 and gave the company an “outperform” rating in a research note on Friday, July 25th. Barclays boosted their price target on Edwards Lifesciences from $90.00 to $95.00 and gave the company an “overweight” rating in a research note on Friday, July 25th. Wells Fargo & Company boosted their price target on Edwards Lifesciences from $84.00 to $88.00 and gave the company an “overweight” rating in a research note on Thursday, August 7th. Finally, Argus raised Edwards Lifesciences to a “strong-buy” rating in a research note on Thursday, July 10th. Three investment analysts have rated the stock with a Strong Buy rating, eleven have issued a Buy rating, eight have given a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and a consensus target price of $86.61.

Edwards Lifesciences Stock Performance

EW opened at $73.80 on Friday. The stock has a market cap of $43.33 billion, a PE ratio of 10.62, a P/E/G ratio of 3.59 and a beta of 1.07. The company has a current ratio of 4.68, a quick ratio of 3.87 and a debt-to-equity ratio of 0.06. Edwards Lifesciences has a 1 year low of $64.00 and a 1 year high of $83.00. The stock’s 50 day simple moving average is $78.59 and its 200-day simple moving average is $75.58.

Edwards Lifesciences (NYSE:EW) last announced its quarterly earnings results on Thursday, July 24th. The medical research company reported $0.67 EPS for the quarter, beating the consensus estimate of $0.62 by $0.05. The business had revenue of $1.53 billion for the quarter, compared to analyst estimates of $1.49 billion. Edwards Lifesciences had a return on equity of 15.01% and a net margin of 72.96%.Edwards Lifesciences’s quarterly revenue was up 11.9% on a year-over-year basis. During the same quarter in the previous year, the firm earned $0.70 EPS. Edwards Lifesciences has set its Q3 2025 guidance at 0.540-0.60 EPS. FY 2025 guidance at 2.400-2.500 EPS. Sell-side analysts forecast that Edwards Lifesciences will post 2.45 EPS for the current year.

Insiders Place Their Bets

In other Edwards Lifesciences news, VP Daniel J. Lippis sold 4,114 shares of the business’s stock in a transaction on Monday, July 28th. The stock was sold at an average price of $79.46, for a total value of $326,898.44. Following the transaction, the vice president owned 22,002 shares of the company’s stock, valued at approximately $1,748,278.92. The trade was a 15.75% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, insider Larry L. Wood sold 8,950 shares of the business’s stock in a transaction on Monday, August 18th. The stock was sold at an average price of $78.06, for a total value of $698,637.00. Following the completion of the transaction, the insider directly owned 206,900 shares in the company, valued at approximately $16,150,614. This represents a 4.15% decrease in their position. The disclosure for this sale can be found here. 0.34% of the stock is currently owned by insiders.

Hedge Funds Weigh In On Edwards Lifesciences

Large investors have recently made changes to their positions in the company. Quantbot Technologies LP acquired a new position in shares of Edwards Lifesciences during the first quarter valued at $26,000. SouthState Corp acquired a new position in shares of Edwards Lifesciences during the first quarter valued at $27,000. Rosenberg Matthew Hamilton acquired a new position in shares of Edwards Lifesciences during the second quarter valued at $28,000. Global X Japan Co. Ltd. lifted its stake in shares of Edwards Lifesciences by 116.1% during the first quarter. Global X Japan Co. Ltd. now owns 402 shares of the medical research company’s stock valued at $29,000 after acquiring an additional 216 shares during the period. Finally, Tradewinds Capital Management LLC lifted its stake in shares of Edwards Lifesciences by 102.5% during the first quarter. Tradewinds Capital Management LLC now owns 405 shares of the medical research company’s stock valued at $29,000 after acquiring an additional 205 shares during the period. Institutional investors and hedge funds own 79.46% of the company’s stock.

About Edwards Lifesciences

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband names.